@article{8741425,
  abstract     = {{STUDY QUESTION: Does gender-affirming treatment prevent full spermatogenesis in transgender women (TW)?

SUMMARY ANSWER: Adequate hormonal therapy (Hi) leads to complete suppression of spermatogenesis in most TW, if serum testosterone levels within female reference ranges are obtained.

WHAT IS KNOWN ALREADY: Gender-affirming treatment in transgender individuals may involve gender-affirming HT. The effects on spermatogenesis in TW remain unclear. In order to add information from a referral centre for transgender care, we wish to compare results of earlier studies with our population of TW who received a standard hormone treatment.

STUDY DESIGN, SIZE, DURATION: This was a prospective cohort study part of the European Network for the Investigation of Gender Incongruence (ENIGI), conducted between 15 February 2010 and 30 September 2015. There were 162 NV were included in the ENIGI study at the Ghent University Hospital in Belgium. Participants are included in ENIGI when they first start HT, and follow-up visits occur over the next 3 years.

PARTICIPANTS/MATERIALS, SETTING METHODS: The study included 97 TW who initiated HT with cyproterone acetate (CPA) plus oestrogens and proceeded with gonadectomy at the Ghent University Hospital. Testicular tissue retrieved during gonadectomy was processed and stained for four different germ cell markers by the Biology of the Testis lab at the Vrije Universiteit Brussel. Subsequent immunohistochemical staining was performed for melanoma-associated antigen A4 (MAGE-A4, marker for spermatogonia and early spermatocytes), boule homologue, RNA-binding protein (BOLL, marker for secondary spermatocytes and round spermatids), cAMP-responsive element modulator (CREM, marker for round spermatids) and acrosin (marker for acrosome visualization). Serum levels of sex steroids were measured prior to surgery.

MAIN RESULTS AND THE ROLE OF CHANCE: Suppressed testosterone levels (<50 ng/dI) were found in 92% of the participants prior to surgery. The mean time between initiation of HT and surgery was 685 days. In 88% (85/97) of the sections, MAGE-A4 staining was positive. Further staining could not reveal complete spermatogenesis in any participant.

LIMITATIONS, REASONS FOR CAUTION: Testicular function of the participants prior to initiation of HT was not assessed, although all participants presented with cisgender male serum testosterone values before initiation of HT. The current study only reports on people using CPA at a fixed dose and may therefore not be applicable to all TW.

WIDER IMPLICATIONS OF THE FINDINGS: HT leads to complete suppression of spermatogenesis in most TW, if serum testosterone levels within female reference ranges are obtained. Serum testosterone levels are associated with the sperm maturation rate. It is important to discuss sperm preservation before the start of hormone therapy. If serum testosterone levels remain higher, spermatogenesis may still occur.}},
  author       = {{Vereecke, Gertjan and Defreyne, Justine and Van Saen, Dorien and Collet, Sarah and Van Dorpe, Jo and T'Sjoen, Guy and Goossens, Ellen}},
  issn         = {{0268-1161}},
  journal      = {{HUMAN REPRODUCTION}},
  keywords     = {{Obstetrics and Gynecology,Rehabilitation,Reproductive Medicine,transgender women,testosterone,spermatogenesis,anti-androgens,oestrogens,QUALITY-OF-LIFE,SEX REASSIGNMENT,SERTOLI-CELLS,INHIBIN-B,TESTIS,THERAPY,HORMONE,TRANSSEXUALS,MORPHOLOGY,SURGERY}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{5--15}},
  title        = {{Characterisation of testicular function and spermatogenesis in transgender women}},
  url          = {{http://doi.org/10.1093/humrep/deaa254}},
  volume       = {{36}},
  year         = {{2021}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: